New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
11:59 EDTCELGCelgene weakness an overreactions, says Wells Fargo
Wells Fargo said Celgene weakness related to the upcoming Markman hearing and the UK's The National Institute for Health and Care Excellence guidance that thalidomide vs. Revlimid should be considered in most second line MM patients is an overreaction. The firm said the Markman hearing has been an overhang but there are many steps needed before a final outcome and that the UK's decision is not meaningful given current reimbursement is only for 3rd+ line anyway. The firm would use weakness in Celgene as a buying opportunity and reiterates its Outperform rating.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
17:08 EDTCELGCelgene announces phase 2 Apremilast data
Subscribe for More Information
April 13, 2015
09:34 EDTCELGActive equity options trading on open
Subscribe for More Information
05:09 EDTCELGCelgene to purchase 14.35M shares of Mesoblast stock for A$3.82 per share
Subscribe for More Information
April 12, 2015
19:33 EDTCELGCelgene takes stake in Australia's Mesoblast, the Australian says
Subscribe for More Information
April 7, 2015
07:24 EDTCELGCelgene Otezla has growing opportunity, says Bernstein
After interviewing small groups of New York City area dermatologists, Bernstein believes that Celgene's psoriasis,treatment, Otezla, has a growing opportunity, due to its oral dosing, convenience, and lack of immunosuppression. The firm quotes doctors as saying that the drug serves as a useful "stepping stone," for patients who might need more intensive therapy, but want to postpone or avoid biologic Bernstein keeps a $158 price target and Outperform rating on Celgene.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use